Ocumetics Announces Completion of Unit Private Placement

Ocumetics Announces Completion of Unit Private Placement

(TheNewswire)

Ocumetics Technology Corp.

Calgary, Alberta TheNewswire - August 15, 2023.  Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) announces that it has completed the private placement previously announced by the Corporation on June 22, 2023.

The Corporation issued an aggregate of 3,333,333 units (" Units ") pursuant to the private placement, at a price of $0.30, for total gross proceeds of $1,000,000.  Each Unit consists of one common share in the share capital of the Corporation (" Common Share ") and one-half of one common share purchase warrant.  Each whole warrant (" Warrant ") entitles the holder to purchase one additional Common Share at an exercise price of $0.60 for a period of two years from the date of issuance of the Warrant.

The Corporation completed an initial tranche of the private placement on July 21, 2023 whereby it issued an aggregate of 1,880,868 Units for aggregate gross proceeds of $564,260.40.

On August 14, 2023, the Corporation completed a second tranche of the private placement to issue a further 1,452,465 Units for aggregate gross proceeds of $435,739.60.

The Corporation paid finders fees to Leede Jones Gable Inc. consisting of cash commissions of $852.99.

100% of the net proceeds are expected to be used for ongoing research and development, although the actual allocation of proceeds may vary from the uses set out above, depending upon future operations, events or opportunities.

All securities issued under the Private Placement are subject to a hold period of four months and one day.

Closing of the Private Placement was subject to the conditional approval from the TSX Venture Exchange, which was obtained.

About Ocumetics

Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that specializes in adaptive lens designs.  Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry.  Ocumetics has developed an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses.  It is designed to allow the eye's natural muscle activity to shift focus from distance to near.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns                                Dayton Marks

President and CEO                        Director

(817) 874-7564                                (778) 347-2500

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation.  Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Corporation mentioned above.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.  The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Copyright (c) 2023 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

OTC:CA
Ocumetics Technology

Ocumetics Technology Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Ocumetics Technology

Ocumetics Technology


Keep reading...Show less
Ocumetics Announces Offering of up to $4 million of Secured Convertible Debentures

Ocumetics Announces Offering of up to $4 million of Secured Convertible Debentures

(TheNewswire)

Ocumetics Technology Corp.

Calgary, Alberta TheNewswire - May 15, 2024.  Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a non-brokered private placement of secured convertible debentures having an aggregate face value principal amount of up to $4,000,000 (the " Principal ").  The debentures will be subject to an original issue discount of 6%, resulting in net available funds to the Corporation of up to $3,760,000 (the " Net Proceeds ").   Debentures will bear interest at rate of 18% per annum, compounded annually.  The Debentures will mature, and Principal and interest will be payable by the Corporation, on the date which is two years from the date of issue.  The Corporation may prepay the indebtedness under the debentures at any time upon ninety (90) days prior written notice, without penalty.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Ocumetics Technology Corp  To Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar

Ocumetics Technology Corp To Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar

(TheNewswire)

Ocumetics Technology Corp.

Calgary, Alberta TheNewswire - February 29, 2024 - Ocumetics Technology Corp. ("Ocumetics") (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO), is pleased to invite investors and other interested parties to attend an upcoming interview with Market Radius Research.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Ocumetics Announces Extension of Private Placement

Ocumetics Announces Extension of Private Placement

(TheNewswire)

Ocumetics Technology Corp.

Calgary, Alberta TheNewswire - December 21, 2023 - Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) is pleased to announce that the TSX Venture Exchange has granted a 15-day extension to close the Corporation's non-brokered private placement announced on November 15, 2023. The new closing deadline for the private placement is January 15, 2024.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Ocumetics Announces December 20, 2023 Webinar regarding Successful Completion of Animal Study

Ocumetics Announces December 20, 2023 Webinar regarding Successful Completion of Animal Study

(TheNewswire)

Ocumetics Technology Corp.

Ocumetics Technology Corp. (" Ocumetics ") ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) a pioneer in the field of ophthalmic innovation, announces a webinar to discuss the successful completion of its biocompatibility animal study and its upcoming first-in-human study, anticipated to commence in Q1 2024 in the Dominican Republic

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Ocumetics Announces Successful Completion of Animal Study Q1 2024 First in Human Study Planned

Ocumetics Announces Successful Completion of Animal Study Q1 2024 First in Human Study Planned

(TheNewswire)

Ocumetics Technology Corp.

Calgary, Alberta TheNewswire - December 7, 2023 - Ocumetics Technology Corp. (" Ocumetics ") ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO), a pioneer in the field of ophthalmic innovation, proudly confirms the successful completion of its biocompatibility animal study, in preparation for its first-in-human study, anticipated to commence in Q1 2024 in the Dominican Republic.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the U.S. District Court for the Western District of Washington issued an order providing for preliminary approval of a proposed settlement of the claims asserted nominally on behalf of Athira against the individual defendants named in the previously disclosed stockholder derivative actions entitled Bushansky v. Kawas et al. No. 2:22-cv-497 and Houlihan v. Kawas et al ., No. 2:22-cv-620, pending before the court. The proposed settlement calls for Athira to adopt certain corporate governance reforms and pay lead plaintiffs' attorney's fees, litigation expenses, and lead plaintiff service awards.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Praxis Precision Medicines Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming conferences.

  • Praxis management will participate in a fireside chat at the H.C. Wainwright 2 nd Annual BioConnect Investor Conference, taking place in New York, NY at the NASDAQ Stock Exchange on May 20, 2024 at 10:00am EDT. A live webcast of the fireside chat will be available through this link and will also be available through the "Upcoming & Recent Events" page of the Investors + Media section of the company's website www.praxismedicines.com . A replay of the webcast will be available on Praxis' website for 90 days following the event.

  • Praxis management will also participate in the Mizuho Securities USA Neuroscience Summit, taking place in Boston, MA on May 21, 2024.

  • Praxis management will also be participating in a fireside chat at the Jefferies Global Healthcare Conference, taking place in New York, NY on June 6, 2024 at 11:30am EDT. A live webcast of the fireside chat will be available through this link and will also be available through the "Upcoming & Recent Events" page of the Investors + Media section of the company's website www.praxismedicines.com . A replay of the webcast will be available on Praxis' website for 90 days following the event.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook , LinkedIn and Twitter/X .

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635

Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 11, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the new non-executive employees received options to purchase 52,590 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $4.50, which was the closing price of Annexon's common stock on May 15, 2024, the date of grant, and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to continued service through the applicable vesting dates.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 2 nd BioConnect Investor Conference at the NASDAQ world headquarters in New York City.

Event H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Date May 20th, 2024
Time 12:00 PM Eastern Time
Link Fireside Chat [ Link ]

About Nuvectis Pharma, Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2024.

Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "We reached an important clinical development milestone in the first quarter of 2024.  Enrollment was completed in two ongoing clinical trials to evaluate HCW9218 in solid tumors.  We are encouraged by the number of patients with evidence of stable disease, even though it is difficult of generalize from Phase 1 and Phase 1b results. We are following our strategy to participate in fully randomized Phase 2 clinical trials in difficult-to-treat cancer indications, working with leading clinical sites.  Using this strategy, we believe we can cost effectively evaluate HCW9218 as a single arm in a larger study.  We intend to advance our cancer studies in ovarian and pancreatic cancer, while seeking to opportunistically participate in other cancer trials that have strong sponsors with financial support."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease expected in second half of 2024

Submitted Investigational New Drug application to U.S. Food and Drug Administration for ATH-1105 for the treatment of amyotrophic lateral sclerosis; On track to dose subjects in a first-in-human study in second quarter of 2024

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Ocumetics Technology

Ocumetics Technology Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×